$QURE

Balachandran Madhavan sold $54K of QURE

Balachandran Madhavan sold 1,993 shares of uniQure N.V. (QURE) at $27.06 on 2026-06-11.

Original reporting
SEC EDGAR · Balachandran Madhavan
Published Jun 12, 2026, 9:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QURE
Bearish
medium confidence
Mentioned
$QURE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QUREBearishLow
01

Why it matters

Discloses a director’s open-market sale of 1,993 shares at a stated average price; no other company-specific news is included.

02

Market read

Traders may treat the disclosure as a small sentiment datapoint, but it is unlikely to drive a major repricing without additional catalysts.

03

What to watch

Transaction size is relatively small, and the filing does not include any accompanying operational/regulatory/clinical update that would re-rate the stock.

Relevance 3/10Novelty 8/10Timing: filed 2026-06-12 (covers sale dated 2026-06-11)

Background

The article is an SEC Form 4 insider transaction disclosure for uniQure N.V. (QURE).

Company-level read

Ticker impact

$QUREBearishMedium confidence
Context

uniQure director Balachandran Madhavan sold 1,993 shares in an open-market transaction on 2026-06-11 at $27.0600/share (Form 4).

Expected impact

Low-to-moderate near-term downside bias versus peers, with limited follow-through absent other catalysts.

Evidence & confidence

The filing is a primary-source insider transaction, but the disclosed size (~$54k) is small and there is no 10b5-1 plan stated, which can increase interpretive noise rather than establish a new fundamental driver.

Market effects

No direct sector read-across; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for diversification or liquidity needs; the absence of a stated 10b5-1 plan doesn’t necessarily imply negative fundamentals.

Key entities

  • uniQure N.V.

    Subject of the Form 4 insider transaction disclosure.

  • Balachandran Madhavan

    Director who sold shares; holdings after transaction reported.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QUREHighAI 9/10

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)

uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.

Med

UniQure Shares Fall After Barclays Downgrade

UniQure's shares declined after Barclays downgraded the company from Overweight to Equal Weight. The stock is currently trading at $22.81, down 2.77% on the day and 41.83% year-to-date. The downgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

$QUREMedAI 8/10

RBC Capital cuts uniQure stock price target on trial data

RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.